Bruce N. Cronstein, MD. Joins Revive Therapeutics as Medical Advisor

TORONTO, ONTARIO--(Marketwired - April 15, 2015) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV), a clinical-stage company focused on commercializing treatments for gout and orphan drug indications, today announced that Dr. Bruce Cronstein, M.D. will join the Company as a medical advisor.

Dr. Cronstein received his MD from the University of Cincinnati. After training in Internal Medicine at the University of Cincinnati and Lenox Hill Hospital in New York City, he completed a fellowship in Rheumatology at NYU School of Medicine. Dr. Cronstein is the senior editor of Inflammation and Current Rheumatology Reports, and has chaired the Arthritis, Connective Tissue and Skin Diseases Study Section of the National Institutes of Health (NIH). A practicing rheumatologist for more than 30 years, Dr. Cronstein is the recipient of a 'Research Hero' award from the Arthritis Foundation and a Clinical Investigator Award from the NIH. In addition to being the author of over 220 peer-reviewed journal papers and multiple patents and patents pending, and an investigator of a number of clinical studies in gout, Dr. Cronstein is the 2013 recipient of the Lee C. Howley Sr. Prize for Research in Arthritis from the Arthritis Foundation.

"We are very excited to have such a noted physician and researcher in inflammation as Dr. Cronstein on our team," said Fabio Chianelli, Chief Executive Officer of Revive. "We believe Dr. Cronstein's vast experience in inflammation, and leadership as an investigator of clinical studies in the treatment of gout, will be instrumental in helping Revive advance further towards its goal of commercializing Bucillamine."

"I am very excited to assist in Revive's clinical development program for gout, which is currently in a Phase IIa study in the United States," said Dr. Cronstein, Medical Advisor for Revive. "Treatment of acute gout flares can be very challenging due to patient specifics, and the development of new safe and effective therapies will benefit the many patients who suffer from the pain and disability of these flares without recourse to any effective treatment."

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSX VENTURE:RVV) is a clinical-stage company focused on commercializing treatments for gout and orphan drug indications such as Cystinuria, Wilson disease and Rett syndrome. Additional information on Revive is available at www.revivethera.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward looking statements in this news release include, without limitation, statements regarding: the closing of the Offering and the use of proceeds therefrom; the Company's drug research and development plans; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations.
In formulating the forward-looking statements contained herein, management has assumed that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive, that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates, that such approvals will be received on a timely basis, and that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect. Factors that may cause actual results to differ materially from those anticipated by these forward looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Annual Information Form for the period ended June 30, 2014 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.